Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00343577
Status:
COMPLETED
Last Update Posted:
2013-11-19
First Post:
2006-06-21
Brief Title:
Antiproteinuric Agents and Fabry Disease
Sponsor:
University of Alabama at Birmingham
Organization:
University of Alabama at Birmingham
Study Overview
Official Title:
Observational Study of Antiproteinuric Agents in Patients With Fabry Disease Treated With Enzyme Replacement Therapy
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Fabry disease is a rare disorder that often has kidney involvement with increased urine protein excretion Proteinuria is recognized as an important risk factor for progression of chronic kidney disease Our hypothesis is that using drugs that reduce urine protein excretion ACE inhibitors and ARBs will have a beneficial effect on patients with Fabry disease who already are receiving enzyme replacement therapy A longitudinal observational study is being undertaken to determine the utility of these agents in Fabry disease realizing that these agents are primarily indicated for reducing systemic blood pressure and most patients with Fabry disease have relatively low blood pressures at baseline
Detailed Description:
Fabry disease is a rare disorder that often has kidney involvement with increased urine protein excretion Proteinuria is recognized as an important risk factor for progression of chronic kidney disease Our hypothesis is that using drugs that reduce urine protein excretion ACE inhibitors and ARBs will have a beneficial effect on patients with Fabry disease who already are receiving enzyme replacement therapy A longitudinal observational study is being undertaken to determine the utility of these agents in Fabry disease realizing that these agents are primarily indicated for reducing systemic blood pressure and most patients with Fabry disease have relatively low blood pressures at baseline
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None